ロード中...
Belimumab for systemic lupus erythematosus
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. OBJECTIVES: To assess the benefits and harms of belimumab (alone or in combination) in system...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2021
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095005/ https://ncbi.nlm.nih.gov/pubmed/33631841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010668.pub2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|